Success Rates Falling for Experimental Drugs

The success rate in bringing new medicines to market is only about half of what it used to be.

A study covering the years 2004 through 2010 found that the overall FDA approval rate is about one in 10, down from one in five to one in six seen in reports from earlier years.  The study reviewed more than 4,000 drugs from companies large and small.

Reuters reports:

“When broken down by therapeutic categories, the highest overall success rate from Phase 1 through likelihood of approval was infectious diseases, such as hepatitis and HIV drugs, at 12 percent, followed by endocrine system drugs, featuring diabetes treatments, at 10.4 percent, and autoimmune diseases, such as rheumatoid arthritis, at 9.4 percent, the study found.”

+ Sources and References
Click Here and be the first to comment on this article
Post your comment